Julian Read, Simris Group CEO, said “The ideal ADC-payload is highly effective at killing cancer cells whilst not damaging healthy cells. Our new patent application describes Simris’ unique approach to making structural optimisations of microcystins for use in an ADC. The free microcystin molecules created have been shown to have a significantly improved efficacy and safety profile. Such results are highly encouraging and suggest that we can create ADC-payloads that set a new benchmark for safety. The next phase is to create ADCs carrying such payloads and test these to gather the efficacy and safety data that we can share with drug developers seeking to develop next-generation ADCs.”

Simris also confirms that its original method patent for modifying and producing payloads for ADCs, Antibody Antibiotic Conjugates (AACs) and beyond has now been granted in Israel. Simris’ technology platform is currently fully patent protected in key markets including Europe, UK, USA, Australia, Japan, and Middle East.

“Whilst the status of our original patent applications are still pending in China, South Korea and India, we are confident that we be successful in these markets too. Protecting the science behind our inventions is a central part of our strategy. The granting of such method patents is vital to our ability to generate significant revenues from license agreements, research collaborations and the production of payloads at scale for the clinical phases and the commercial market”, added Julian Read.